New leadership for Mundipharma ANZ with Jane Orr announcing retirement

The association says it is 'astonished' after the federal government disregarded the findings of a Senate inquiry, failed to consult, and used the last day of the parliamentary sitting year to table enabling legislation that will cut the value of the R&D Tax Incentive.

AstraZeneca's LYNPARZA (olaparib) will be funded for ovarian cancer in New Zealand - three years after the company submitted an application to PHARMAC.

"Patients will now have greater choice as to where they can receive treatment, at home or via a healthcare professional," said the company.

An alliance of 22 Australian consumer groups has come together to call on governments to implement a range of reforms including an independent review of Australia’s Health Technology Assessment system.

Another confirmed speaker for the BioPharmaDispatch 2020 conference with the Australian general manager of one of the world's emerging Artifical Intelligence companies.

As "transparent as possible" presumably means stakeholders should gain a proper understanding of how decisions are made. Surely this extends to understanding how discussants review and present submissions, what they are recommending, and the extent to which the PBAC accepts their advice.

According to Christi Kelsey, general manager for GSK Australia’s pharmaceuticals business, “At GSK we believe that when we grow as an individual, we grow as a business, and that volunteering for one of our charitable partners provides an opportunity to grow."

CSL invested over A$1.2 billion in R&D in financial year 2019 as the company progressed what it described as a "highly differentiated product portfolio mix".

If the industry or individual companies are concerned or even oppose the push to include more information in PBAC Public Summary Documents, the Department of Health has just provided the argument to stop it happening.

The reality is that, based on the Department of Health's response to the FoI on discussant presentations, the industry could rightly argue for the complete abolition of Public Summary Documents and against the release of any information they provide in submissions.